Tissue culture, sequencing, and immunological reagents

The Food and Drug Administration is forecasting a new priority requirement for the procurement of tissue culture, sequencing, and immunological reagents. The scope of this acquisition includes RNA sequencing, SBA and OPA materials, human carriage kits, and various tissue culture and immunoassay supplies. This opportunity is managed by the Food and Drug Administration, with the Cber Acquisition Liaison serving as the primary program point of contact. While a specific contracting officer has not yet been named, the requirement is categorized as a priority two new requirement.